Brookline Capital Management Predicts FBRX Q2 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Equities research analysts at Brookline Capital Management issued their Q2 2025 earnings per share (EPS) estimates for shares of Forte Biosciences in a research report issued on Thursday, April 3rd. Brookline Capital Management analyst K. Raja forecasts that the company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Forte Biosciences’ current full-year earnings is ($12.12) per share. Brookline Capital Management also issued estimates for Forte Biosciences’ Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.60) EPS and FY2029 earnings at ($4.22) EPS.

A number of other analysts have also commented on the stock. Chardan Capital cut their price objective on shares of Forte Biosciences from $64.00 to $61.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. TD Cowen initiated coverage on shares of Forte Biosciences in a research report on Tuesday, January 21st. They set a “buy” rating on the stock.

Forte Biosciences Stock Down 9.2 %

NASDAQ:FBRX opened at $5.34 on Monday. The company has a market cap of $35.15 million, a P/E ratio of -0.33 and a beta of 2.52. Forte Biosciences has a twelve month low of $4.11 and a twelve month high of $28.68. The business has a 50 day moving average price of $9.34 and a two-hundred day moving average price of $11.66.

Institutional Investors Weigh In On Forte Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in FBRX. Woodline Partners LP bought a new position in shares of Forte Biosciences in the fourth quarter valued at $4,639,000. Tybourne Capital Management HK Ltd. lifted its stake in Forte Biosciences by 327.6% in the fourth quarter. Tybourne Capital Management HK Ltd. now owns 619,981 shares of the company’s stock valued at $14,080,000 after acquiring an additional 475,000 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of Forte Biosciences in the 4th quarter valued at about $13,626,000. Fred Alger Management LLC increased its stake in shares of Forte Biosciences by 1,271.2% during the 4th quarter. Fred Alger Management LLC now owns 1,133,944 shares of the company’s stock worth $25,752,000 after purchasing an additional 1,051,246 shares during the last quarter. Finally, BVF Inc. IL raised its holdings in shares of Forte Biosciences by 398.2% in the 4th quarter. BVF Inc. IL now owns 594,282 shares of the company’s stock valued at $13,496,000 after purchasing an additional 475,000 shares during the period. Institutional investors own 77.63% of the company’s stock.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.